Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aslan Pharma In-licenses Novel Asthma Therapy from CSL

publication date: May 12, 2014
Aslan Pharma of Singapore signed a global license agreement to develop an anti-IL13 receptor monoclonal antibody from CSL Limited, an Australian biopharma. The molecule, CSL334, is currently in preclinical development for the treatment of asthma. Aslan will be responsible for developing CSL334 through clinical proof-of-concept, primarily in Asia. At that time, Aslan will identify a global partner for the Phase III trial and commercialization. CSL will receive a portion of the proceeds, though further financial details were not disclosed. More details....

Stock Symbol: (ASX: CSL)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital